Establishment of a semi-continuous scale-down clone screening model for intensified perfusion culture
Biotechnology Letters · 2024
DOI: 10.1007/s10529-024-03512-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Letters, 2024. Verfasst von Tao Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cell Line Development, WuXi Biologics, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China. Hauptthemen laut MEDLINE: Bioreactors, Cricetulus, Cell Culture Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Perfusion cultures have been extensively used in the biotechnology industry to achieve high yields of recombinant products, especially those with stability issue. The WuXiUP™ platform represents a novel intensified perfusion that can achieve ultra-high productivity. This study describes a representative scale-down 24-deep well plate (24-DWP) cell culture model for intensified perfusion clone screening. METHODS: Clonal cell lines were expanded and evaluated in 24-DWP semi-continuous culture. Cell were sampled and counted daily with the aid of an automated liquid handler and high-throughput cell counter. To mimic perfusion culture, 24-DWP plates were spun down and resuspended with fresh medium daily. Top clones were ranked based on growth profiles and productivities. The best performing clones were evaluated on bioreactors. RESULTS: The selected clones achieved volumetric productivity (Pv) up to 5 g/L/day when expressing a monoclonal antibody, with the accumulative harvest Pv exceeding 60 g/L in a 21-day cell culture. Product quality attributes of clones cultured in 24-DWP were comparable with those from bioreactors. A high seeding strategy further shortened the clone screening timeline. CONCLUSION: In this study, a 24-DWP semi-continuous scale-down model was successfully developed to screen for cell lines suitable for intensified perfusion culture.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Line Development, WuXi Biologics, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
- Bioprocess Research & Development, WuXi Biologics, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
- Biologics Development, WuXi Biologics, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
- Cell Line Development, WuXi Biologics, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China. sam.zhang@wuxibiologics.com.
Zitieren
APA
Sun, T., Zhang, Y., Liang, H., Fang, W., Qian, Z., Tan, K. W., Li, J., Zheng, X., Fang, M., Zhou, H., Zhou, W., & Zhang, S. (2024). Establishment of a semi-continuous scale-down clone screening model for intensified perfusion culture. Biotechnology Letters. https://doi.org/10.1007/s10529-024-03512-0
Vancouver
Sun T, Zhang Y, Liang H, Fang W, Qian Z, Tan KW, et al. Establishment of a semi-continuous scale-down clone screening model for intensified perfusion culture. Biotechnology Letters. 2024. doi:10.1007/s10529-024-03512-0
BibTeX
@article{Sun2024,
author = {Sun, Tao and Zhang, Yu and Liang, Hengrui and Fang, Wenjing and Qian, Zichen and Tan, Kee Wee and Li, Junjie and Zheng, Xiang and Fang, Mingyue and Zhou, Hang and Zhou, Weichang and Zhang, Sam},
title = {Establishment of a semi-continuous scale-down clone screening model for intensified perfusion culture},
journal = {Biotechnology Letters},
year = {2024},
doi = {10.1007/s10529-024-03512-0}
}
EUVIMED